Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
SEVERE ALLERGIC REACTIONS
GRASTEK tablets contain pollen allergen extract from Timothy grass (Phleum pratense). GRASTEK is a sublingual tablet.
GRASTEK is available as a tablet of 2800 BAU of Timothy grass pollen allergen extract.
Inactive ingredients: gelatin NF (fish source), mannitol USP and sodium hydroxide NF.
GRASTEK® is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. GRASTEK is approved for use in persons 5 through 65 years of age.
GRASTEK is not indicated for the immediate relief of allergic symptoms.
For sublingual use only.
One GRASTEK tablet daily.
Administer the first dose of GRASTEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. After receiving the first dose of GRASTEK, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local allergic reaction. If the patient tolerates the first dose, the patient may take subsequent doses at home.
Administer GRASTEK to children under adult supervision.
Take the tablet from the blister unit after carefully removing the foil with dry hands.
Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.
Wash hands after handling the tablet.
Do not take the tablet with food or beverage. Food or beverage should not be taken for the following 5 minutes after taking the tablet.
Initiate treatment at least 12 weeks before the expected onset of each grass pollen season and continue treatment throughout the season. For sustained effectiveness for one grass pollen season after cessation of treatment, GRASTEK may be taken daily for three consecutive years (including the intervals between the grass pollen seasons). The safety and efficacy of initiating treatment in season have not been established.
Data regarding the safety of restarting treatment after missing a dose of GRASTEK are limited. In the clinical trials, treatment interruptions for up to seven days were allowed.
Prescribe auto-inject able epinephrine to patients prescribed GRASTEK and instruct them in the proper use of emergency self-injection of epinephrine [see WARNINGS AND PRECAUTIONS].
GRASTEK is available as 2800 Bioequivalent Allergy Unit (BAU) tablets that are white to off-white, circular with a debossed round detail on one side.
GRASTEK 2800 BAU tablets are white to off-white, circular sublingual tablets with a debossed round detail on one side.
GRASTEK is supplied as follows:
3 blister packages of 10 tablets (30 tablets total). NDC 52709-1501-3
Store at controlled room temperature 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C(59°F-86°F). Store in the original package until use to protect from moisture.
Manufactured by: Catalent Pharma Solutions Limited, Blagrove, Swindon, Wiltshire, SN5 8RU UK. Revised: Sep 2022
Adverse reactions reported in ≥5% of patients were: ear pruritus, oral pruritus, tongue pruritus, mouth edema, and throat irritation.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety data described below are based on 6 clinical trials which randomized 3589 subjects 18 through65 years of age with Timothy grass pollen induced rhinitis with or without conjunctivitis, including1669 subjects who were exposed to at least one dose of GRASTEK. Of the subjects treated with GRASTEK,25% had mild asthma and 80% were sensitized to other allergens in addition to grass. The subject population was 88% White, 7% African American, and 3% Asian. Subjects were 52% male, and 88% of subjects were between 18 and 50 years of age. Subject demographics in placebo-treated subjects were similar to the active group.
The most common adverse reactions reported in subjects treated with GRASTEK were oral pruritus (26.7%vs 3.5% placebo), throat irritation (22.6% vs 2.8%), ear pruritus (12.5% vs 1.1%) and mouth edema (11.1% vs0.8%). The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to GRASTEK or placebo was 4.9% and 0.9%, respectively. The most common adverse reactions that led to study discontinuation in subjects who were exposed to GRASTEK were pharyngeal edema and oralpruritus.
Seven adult subjects (7/1669; 0.4%) who received GRASTEK experienced treatment-related systemic allergic reactions that led to discontinuation of GRASTEK in four out of the seven subjects.
Adverse reactions reported in ≥1% of subjects treated with GRASTEK are shown in Table 1.
Table 1: Adverse Reactions Reported in ≥1% of Adults Treated with GRASTEK
| Adverse Reaction | GRASTEK (N=1669) |
PLACEBO (N=1645) |
| Nervous System Disorders | ||
| Headache | 2.1% | 1.3% |
| Ear and Labyrinth Disorders | ||
| Ear pruritus | 12.5% | 1.1% |
| Respiratory, Thoracic and Mediastinal Disorders | ||
| Throat irritation | 22.6% | 2.8% |
| Pharyngeal edema | 3.4% | 0.1% |
| Dry throat | 1.7% | 0.4% |
| Oropharyngeal pain | 1.6% | 1.0% |
| Nasal discomfort | 1.6% | 1.0% |
| Throat tightness | 1.4% | 0.2% |
| Dyspnea | 1.1% | 0.4% |
| Gastrointestinal Disorders | ||
| Oral pruritus | 26.7% | 3.5% |
| Mouth edema | 11.1% | 0.8% |
| Paresthesia oral | 9.8% | 2.0% |
| Tongue pruritus | 5.7% | 0.5% |
| Lip swelling | 4.0% | 0.2% |
| Swollen tongue | 2.8% | 0.1% |
| Dyspepsia | 2.3% | 0.1% |
| Hypoesthesia oral | 2.3% | 1.0% |
| Nausea | 1.9% | 0.6% |
| Oral discomfort | 1.6% | 0.3% |
| Oral mucosal erythema | 1.5% | 0.6% |
| Lip edema | 1.3% | 0.1% |
| Glossitis | 1.3% | 0.1% |
| Stomatitis | 1.1% | 0.3% |
| Tongue disorder | 1.1% | 0.2% |
| Tongue edema | 1.1% | 0.4% |
| Glossodynia | 1.0% | 0.3% |
| Dysphagia | 1.0% | 0.2% |
| Palatal edema | 1.0% | 0.1% |
| Skin and Subcutaneous Tissue Disorders | ||
| Pruritus | 2.4% | 1.0% |
| Urticaria | 1.7% | 0.9% |
| General Disorders and Administration Site Conditions | ||
| Chest discomfort | 1.6% | 0.5% |
| Fatigue | 1.4% | 0.4% |
Adverse reactions of interest that occurred in ≤1% of GRASTEK recipients include abdominal pain and gastroesophageal reflux.
Safety data are based on 3 clinical trials which randomized 881 subjects between 5 and 17 years of age withgrass pollen induced rhinitis with or without conjunctivitis. Overall, 445 subjects received at least one dose ofGRASTEK. Of the subjects treated with GRASTEK, 31% had mild asthma and 86% were sensitized to other allergens in addition to grass. The subject population was 86% White, 7% African American and 3% multi-racial. The majority (66%) of subjects were male. The mean age of subjects was 11.7 years. Subject demographics in placebo-treated subjects were similar to the active group.
The most common adverse reactions in pediatric subjects treated with GRASTEK were oral pruritus (24.4%vs 2.1% placebo), throat irritation (21.3% vs 2.5%) and mouth edema (9.8% vs 0.2%). The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to GRASTEK or placebo was 6.3% and 0.7%, respectively.
One pediatric subject (1/447; 0.2%) who received GRASTEK experienced a treatment-related systemic allergic reaction consisting of lip angioedema, slight dysphagia due to the sensation of a lump in the throat, and intermittent cough which was of moderate intensity on Day 1. The subject was treated with epinephrine, recovered, and was discontinued from the trial.
Adverse reactions reported in ≥1% of subjects treated with GRASTEK are shown in Table 2.
Table 2: Adverse Reactions Reported in ≥1% of Pediatric Subjects Treated with GRASTEK
| Adverse Reaction | GRASTEK (N=447) |
PLACEBO (N=434) |
| Nervous System Disorders | ||
| Headache | 3.4% | 1.8% |
| Ear and Labyrinth Disorders | ||
| Ear pruritus | 7.2% | 0.5% |
| Eye Disorders | ||
| Eye pruritus | 3.4% | 2.1% |
| Respiratory, Thoracic and Mediastinal Disorders | ||
| Throat irritation | 21.3% | 2.5% |
| Oropharyngeal pain | 4.0% | 1.4% |
| Pharyngeal erythema | 3.6% | 0.7% |
| Pharyngeal edema | 2.9% | 0% |
| Cough | 2.7% | 1.2% |
| Dyspnea | 2.0% | 0.5% |
| Nasal discomfort | 1.6% | 0.9% |
| Nasal congestion | 1.6% | 0.5% |
| Sneezing | 1.6% | 0.7% |
| Gastrointestinal Disorders | ||
| Oral pruritus | 24.4% | 2.1% |
| Mouth edema | 9.8% | 0.2% |
| Tongue pruritus | 9.2% | 0.9% |
| Lip swelling | 7.2% | 0.5% |
| Paresthesia oral | 5.4% | 1.2% |
| Oral mucosal erythema | 4.9% | 0.9% |
| Lip pruritus | 2.9% | 0.2% |
| Swollen tongue | 2.5% | 0% |
| Dysphagia | 2.0% | 0% |
| Nausea | 1.6% | 0.5% |
| Oral discomfort | 1.6% | 0.2% |
| Stomatitis | 1.3% | 0% |
| Hypoesthesia oral | 1.1% | 0.2% |
| Glossodynia | 1.1% | 0.2% |
| Skin and Subcutaneous Tissue Disorders | ||
| Urticaria | 1.8% | 0.2% |
| General Disorders and Administration Site Conditions | ||
| Chest discomfort | 2.0% | 0.5% |
In European post-approval studies which included 1,666 patients treated with GRASTEK (marketed under the name GRAZAX), reported serious adverse reactions assessed as related to GRASTEK use included anaphylactic reaction, asthma exacerbation, hoarseness, laryngitis, oral ulceration, and ulcerative colitisexacerbation.
The following adverse reactions have been identified during post-approval use of GRASTEK (marketed under the name GRAZAX in Europe). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These include:
Eosinophilic esophagitis has been reported following treatment with GRASTEK (marketed under the name GRAZAX). The clinical details of some post marketing reports are consistent with a drug-induced effect, Including at least one case with resolution of symptoms upon discontinuation of GRASTEK, relapse after resuming GRASTEK and resolution again after discontinuation of GRASTEK.
No Information provided
Included as part of the PRECAUTIONS section.
GRASTEK can cause systemic allergic reactions including anaphylaxis which may be life-threatening. In addition, GRASTEK can cause severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening. Educate patients to recognize the signs and symptoms of these allergic reactions and instruct them to seek immediate medical care and discontinue therapy should any of these occur. Allergic reactions may require treatment with epinephrine. [See WARNINGS AND PRECAUTIONS]
Administer the initial dose of GRASTEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local allergic reaction. Observe patients in the office for at least 30 minutes following the initial dose of GRASTEK.
Prescribe auto-inject able epinephrine to patients receiving GRASTEK. Instruct patients to recognize the signs and symptoms of a severe allergic reaction and in the proper use of emergency auto-inject able epinephrine. Instruct patients to seek immediate medical care upon use of auto-inject able epinephrine and to stop treatment with GRASTEK. [See PATIENT INFORMATION]
See the epinephrine package insert for complete information.
GRASTEK may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious allergic reaction or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function(either chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension.
GRASTEK may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine. These medications include:
Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrineine used to treat serious systemic reactions, including anaphylaxis. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine.
Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis. Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine.
The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxinesodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.
Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of cardiac arrhythmias.
GRASTEK can cause local reactions in the mouth or throat that could compromise the upper airway [see ADVERSE REACTIONS]. Consider discontinuation of GRASTEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.
Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see CONTRAINDICATIONS and ADVERSE REACTIONS]. Discontinue GRASTEK and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastro-esophageal symptoms including dysphagia or chest pain.
GRASTEK has not been studied in subjects with moderate or severe asthma or any subjects who required daily medication to treat asthma.
Withhold immunotherapy with GRASTEK if the patient is experiencing an acute asthma exacerbation. Reevaluate patients who have recurrent asthma exacerbations and consider discontinuation of GRASTEK.
GRASTEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.
Stop treatment with GRASTEK to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers or thrush) or oral wounds, such as those following oralsurgery or dental extraction.
Advise patients to read the FDA-approved patient labeling (Medication Guide) and to keep GRASTEK and all medicines out of the reach of children.
Advise patients that GRASTEK may cause life-threatening systemic or local allergic reactions, including anaphylaxis. Educate patients about the signs and symptoms of these allergic reactions[see WARNINGS AND PRECAUTIONS]. The signs and symptoms of a severe allergic reaction may include: syncope, dizziness, hypotension, tachycardia, dyspnea, wheezing, bronchospasm, chest discomfort, cough, abdominal pain, vomiting, diarrhea, rash, pruritus, flushing, and urticaria.
Ensure that patients have auto-inject able epinephrine and instruct patients in its proper use. Instruct patients who experience a severe allergic reaction to seek immediate medical care, discontinue GRASTEK, and resume treatment only when advised by a physician to do so.[See WARNINGS AND PRECAUTIONS]
Advise patients to read the patient information for epinephrine.
Inform patients that the first dose of GRASTEK must be administered in a healthcare setting under the supervision of a physician and that they will be monitored for at least 30 minutes to watch for signs and symptoms of a life-threatening systemic or local allergic reaction[see WARNINGS AND PRECAUTIONS].
Because of the risk of upper airway compromise, instruct patients with persistent and escalating adverse reactions in the mouth or throat to discontinue GRASTEK and to contact their healthcare professional.[See WARNINGS AND PRECAUTIONS]
Because of the risk of eosinophilic esophagitis, instruct patients with severe or persistent symptoms of esophagitis to discontinue GRASTEK and to contact their healthcare professional. [See WARNINGS AND PRECAUTIONS]
Inform parents/guardians that GRASTEK should only be administered to children under adult supervision [see DOSAGE AND ADMINISTRATION].
Instruct patients with asthma that if they have difficulty breathing or if their asthma becomes difficult to control, they should stop taking GRASTEK and contact their healthcare professional immediately [see WARNINGS AND PRECAUTIONS].
Instruct patients to carefully remove the foil from the blister unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet. [See DOSAGE AND ADMINISTRATION]
No studies have been performed in animals to evaluate the carcinogenic potential of GRASTEK.
There were no positive findings in the in vitro mouse lymphoma and the bacterial reverse mutation assays for mutagenicity using Timothy grass (Phleum pratense) pollen allergen extract.
A combined fertility/developmental toxicity study in male and female mice revealed no evidence of impaired fertility due to Timothy grass pollen allergen extract administered daily prior to mating and during gestation at approximately 6.7 times the human sublingual dose (see Data).
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to4% and 15 to 20%, respectively. Available human data do not establish the presence or absence of GRASTEK-associated risks during pregnancy.
In two reproductive and developmental toxicity studies mice were administered Timothy grass pollen extract daily by buccal cavity at doses approximately 6.7 times the human sublingual dose. In one study doses were administered during gestation and lactation. In the other study doses were administered prior to mating and during gestation. These studies revealed no evidence of harm to the mother or the fetus due to GRASTEK (see Data).
Animal Data
A pre- and postnatal developmental study and a combined fertility/developmental toxicity study were conducted in mice. In these studies, the effect of Timothy grass (Phleum pratense) pollen allergen extract, the active component of GRASTEK, on embryo-fetal development was evaluated. In the pre- and postnatal developmental toxicity study female mice were administered Timothy grass pollen allergen extract bybuccal cavity daily from day 6 of gestation to day 17 of lactation at doses approximately 6.7 times the human sublingual dose. In the combined fertility/developmental toxicity study, female mice were administered Timothy grass pollen allergen extract daily by buccal cavity administration from 14 days prior to mating and until day 15of the gestation period (male animals were administered the same dose daily for 4 weeks before pairing and during pairing) at doses approximately 6.7 times the human sublingual dose. Fertility was normal and there were no treatment-related post-implementation losses, fetal malformations or variations.
It is not known if GRASTEK is excreted in human milk. Data are not available to assess the effect of GRASTEK on milk production or on the breast-fed child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for GRASTEK and any potential adverse effects on the breast-fed child from GRASTEK or from the underlying maternal condition.
Efficacy and safety of GRASTEK have been established in children and adolescents 5 through 17 years of age. The safety and efficacy in pediatric patients below 5 years of age have not been established.
There is no clinical trial experience with GRASTEK in patients over 65 years of age.
No Information provided
GRASTEK is contraindicated in patients with:
The precise mechanisms of action of allergen immunotherapy are not known.
The efficacy of GRASTEK in the treatment of allergic rhinitis with or without conjunctivitis in Timothy grass pollen allergic subjects 5 years of age and older, with or without mild asthma, was evaluated during the first grass pollen season in two trials of approximately 24 weeks treatment duration. The sustained effect of GRASTEK was evaluated in one trial conducted over 5 grass pollen seasons. All three trials were randomized, double-blind, parallel group, multicenter clinical trials. Subjects had a history of grass pollen induced rhinitis with or without conjunctivitis and sensitivity to Timothy grass pollen as determined by specific testing (IgE). In these three studies, subjects initiated GRASTEK or placebo approximately 12 weeks prior to the pollen season. In the long-term study, subjects received GRASTEK or placebo daily for 3 consecutive years and were followed for 2 years without treatment.
Efficacy was established by self-reporting of rhinoconjunctivitis daily symptom scores (DSS) and dailymedication scores (DMS). Daily rhinoconjunctivitis symptoms included four nasal symptoms (runny nose, stuffy nose, sneezing, and itchy nose), and two ocular symptoms (gritty/itchy eyes and watery eyes). The rhinoconjunctivitis symptoms were measured on a scale of 0 (none) to 3 (severe). Subjects in clinical trials were allowed to take symptom-relieving medications (including systemic and topical antihistamines and topical and oral corticosteroids) as needed. The daily medication score measured the use of standard open-label allergymedications. Predefined values were assigned to each class of medication. Generally, systemic and topical antihistamines were given the lowest score, topical steroids an intermediate score, and oral corticosteroids the highest score. The sums of the DSS and DMS were combined into the Total Combined Score (TCS) which was averaged over the entire grass pollen season.
This placebo-controlled trial evaluated 1501 subjects 5 through 65 years of age (approximately 80% were18 years and older) comparing GRASTEK (N=752) and placebo (N=749) administered as a sublingual tablet daily for approximately 24 weeks. The subject population was 84% White, 9% African American and 4%Asian. The majority of subjects were male (52%). In this study, approximately 25% of subjects had mild, intermittent asthma and 85% of all subjects were sensitized to other allergens in addition to grass pollen. Subjects with a clinical history of symptomatic allergies to non-grass pollen allergens that required treatment during the grass pollen season were excluded from the studies. All treatment groups were balanced with regard to baseline characteristics.
Subjects treated with GRASTEK had a decrease in the TCS throughout the grass pollen season compared to placebo-treated subjects. Similarly, the DSS and DMS were decreased in subjects treated with GRASTEK compared to placebo throughout the grass pollen season, and the TCS was decreased compared to placebo during the peak grass pollen season (see Table 3).
Table 3: Total Combined Scores (TCS), Rhinoconjunctivitis Daily Symptom Scores (DSS), and Daily Medication Scores (DMS) During the Grass Pollen Season
| Endpoint* | GRASTEK (N)† Score‡ | Placebo (N)† Score‡ | Treatment Difference (GRASTEK - Placebo) | Difference Relative to Placebo§ Estimate (95% CI) |
| TCS Entire Season | (629) 3.24 | (672) 4.22 | -0.98 | -23% (-36.0, -13.0) |
| TCS Peak Season | (620) 3.33 | (663) 4.67 | -1.33 | -29% (-39.0, -15.0) |
| DSS Entire Season | (629) 2.49 | (672) 3.13 | -0.64 | -20% (-32.0, -10.0) |
| DMS Entire Season | (629) 0.88 | (672) 1.36 | -0.48 | -35% (-49.3, -20.8) |
| TCS=Total Combined Score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score. * Non-parametric analysis for TCS and DSS endpoints: Parametric analysis using zero-inflated log-normal model for DMS. † Number of subjects in analyses. ‡ For TCS and DSS endpoints the group medians are reported, treatment difference and that relative to placebo is based on group medians. For DMS, the group means are reported and difference relative to placebo is based on estimated group means. § Difference relative to placebo computed as: (GRASTEK - placebo)/placebo x 100. |
||||
This double-blind clinical trial of approximately 24 weeks duration evaluated 344 pediatric subjects 5 to 17years of age who were treated with either GRASTEK or placebo once daily. The subject population was 88%White, 7% African American, and 2% Asian. The majority (65%) of subjects were male. The mean age of subjects was 12.3 years. In this study, 26% of subjects had mild intermittent asthma and most subjects (89%)were sensitized to other allergens in addition to grass pollen. Subjects with a clinical history of symptomatic allergies to non-grass pollen allergens that required treatment during the grass pollen season were excluded from the studies. All treatment groups were balanced with regard to baseline characteristics.
Pediatric subjects treated with GRASTEK had a decrease in TCS throughout the grass pollen season compared to placebo treated subjects (see Table 4). Similarly, the DSS and DMS were decreased in GRASTEK compared to placebo throughout the grass pollen season.
Table 4: Total Combined Scores (TCS), Rhinoconjunctivitis Daily Symptom Scores (DSS) and Daily Medication Scores (DMS) During the Entire Grass Pollen Season
| Endpoint* | GRASTEK (N=149)† Score‡ | Placebo (N=158)† Score‡ | Treatment Difference (GRASTEK - Placebo) | Difference Relative to Placebo§ Estimate (95% CI) |
| TCS | 4.62 | 6.25 | -1.63 | -26% (-38.2, -10.1) |
| DSS | 3.71 | 4.91 | -1.20 | -24% (-36.4, -9.1) |
| DMS | 0.91 | 1.33 | -0.42 | -32% (-57.7, 4.0) |
| TCS=Total combined score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score. * Parametric analysis using analysis of variance model for all endpoints. † Number of subjects in analyses. ‡ The estimated group means are reported and difference relative to placebo is based on estimated group means. § Difference relative to placebo computed as: (GRASTEK - placebo)/placebo x 100. |
||||
The sustained effect of GRASTEK was measured in a 5-year double-blind study. The study included 634randomized subjects between 18 and 65 years of age. The subject population was 96% White, 2% Asian and 1%African American. The majority (59%) of subjects were male. The mean age of subjects was 34 years. Subjects received either GRASTEK or placebo daily for 3 consecutive years and were then observed for 2 sub sequent years during which they did not receive study drug. Subjects treated with GRASTEK had a decrease in TCS throughout the grass pollen season during the three years of active treatment. This effect was sustained during the grass pollen season in the first year after discontinuation of GRASTEK (see Table 5), but not in the second year.
Table 5: Rhinoconjunctivitis Total Combined Score (TCS), Daily Symptom Score (DSS), and Daily Medication Score (DMS) During the Entire Grass Pollen Season from the 5-Year Study
| Endpoint | Difference Relative to Placebo* (95% CI) |
|||
| Treatment Year 1 N=568† |
Treatment Year 2‡ N=316† |
Treatment Year 3 N=287† |
Post Treatment Year 1 N=257† |
|
| TCS | -34.2% (-42.0%, -26.3%) |
-40.9% (-51.8%, -29.5%) |
-34.0% (-45.5%, -21.4%) |
-27.2% (-39.9%, -12.4%) |
| DSS | -31.2% (-38.8%, -23.4%) |
-36.2% (-46.5%, -26.2%) |
-29.0% (-40.3%, -16.3%) |
-26.2% (-37.6%, -12.2%) |
| DMS | -38.4% (-49.8%, -26.5%) |
-45.5% (-60.4%, -28.2%) |
-40.1% (-55.4%, -21.2%) |
-28.6% (-46.3%, -6.0%) |
| TCS=Total Combined Score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score. *Difference relative to placebo computed as: (GRASTEK - placebo)/placebo x 100. †Number of subjects in analyses. ‡Study extended from 1 to 5 years (site closures, subject unwillingness to participate beyond 1 year). |
||||
GRASTEK ®
(GRAS-tek)
(Timothy Grass Pollen Allergen Extract)
Carefully read this Medication Guide before you or your child start taking GRASTEK and each time you get are fill. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or you want to learn more about GRASTEK.
What is the Most Important Information I Should Know about GRASTEK?
GRASTEK can cause severe allergic reactions that may be life-threatening. Stop taking GRASTEK and get medical treatment right away if you or your child has any of the following symptoms after taking GRASTEK:
For home administration of GRASTEK, your doctor will prescribe auto-inject able epinephrine, a medicine you can inject if you or your child has a severe allergic reaction after taking GRASTEK. Your doctor will train and instruct you on the proper use of auto-inject able epinephrine.
Talk to your doctor or read the epinephrine patient information if you have any questions about the use of auto-inject able epinephrine.
What is GRASTEK?
GRASTEK is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat Timothy and related grass pollen allergies that can cause sneezing, runny or itchy nose, stuffy or congested nose, or itchy and watery eyes. GRASTEK may be prescribed for persons 5 through 65 years of age who are allergic to grass pollen.
GRASTEK is taken for about 12 weeks before grass pollen season and throughout grass pollen season. GRASTEK may also be taken daily for 3 years to provide a sustained effect for a fourth year in which you do not have to take GRASTEK.
GRASTEK is NOT a medication that gives immediate relief for symptoms of grass allergy.
Who Should Not Take GRASTEK?
What Should I Tell My Doctor Before Taking GRASTEK?
Your doctor may decide that GRASTEK is not the best treatment if:
You should tell your doctor if you or your child is taking or has recently taken any other medicines, including medicines obtained without a prescription and herbal supplements. Keep a list of them and show it to your doctor and pharmacist each time you get a new supply of GRASTEK. Ask your doctor or pharmacist for advice before taking GRASTEK.
Are there any reasons to stop taking GRASTEK?
Stop GRASTEK and contact your doctor if you or your child has any of the following after taking GRASTEK:
Also, stop taking GRASTEK following: mouth surgery procedures (such as tooth removal), or if you develop any mouth infections, ulcers or cuts in the mouth or throat.
How should I take GRASTEK?
Take GRASTEK exactly as your doctor tells you.
GRASTEK is a prescription medicine that is placed under the tongue.
Take the first tablet of GRASTEK in your doctor’s office. After taking the first tablet, you or your child will be watched for at least 30 minutes for symptoms of a serious allergic reaction.
If you tolerate the first dose of GRASTEK, you or your child will continue GRASTEK therapy at home by taking one tablet every day. Children should be given each tablet of GRASTEK by an adult who will watch for any symptoms of a serious allergic reaction.
Take GRASTEK as prescribed by your doctor until the end of the treatment course. If you forget to take GRASTEK, do not take a double dose. Take the next dose at your normal scheduled time the next day. If you miss more than one dose of GRASTEK, contact your healthcare provider before restarting.
What are the possible side effects of GRASTEK?
In children and adults, the most commonly reported side effects were itching of the mouth, lips, or tongue, swelling under the tongue, or throat irritation. These side effects, by themselves, were not dangerous or life-threatening.
GRASTEK can cause severe allergic reactions that may be life-threatening. Symptoms of allergic reactions to GRASTEK include:
For additional information on the possible side effects of GRASTEK, talk with your doctor or pharmacist. You may report side effects to the U.S. Food and Drug Administration (FDA) at 1-800-FDA-1088 orwww.fda.gov/med watch.
How should I store GRASTEK?
Keep GRASTEK out of the reach of children.
Throw away any unused GRASTEK after the expiration date which is stated on the carton and blister pack after “EXP.”
Store GRASTEK in a dry place at room temperature, 15°C to 30°C (59°F to 86°F), in the original package.
General information about GRASTEK
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use GRASTEK for a condition for which it was not prescribed. Do not give GRASTEK to other people, even if they have the same symptoms. It may harm them.
This Medication Guide summarizes the most important information about GRASTEK. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about GRASTEK that was written for healthcare professionals. For more information go to www.grastek.com or call toll-free at 1-855-782-9323.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
